



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Lexatumumab

Cat. No.:	HY-P99299
CAS No.:	845816-02-6
Target:	Apoptosis
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lexatumumab (HGS-ETR 2) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. Lexatumumab can be used for malignant pleural mesothelioma (MPM) research ^[1] .								
IC₅₀ & Target	TRAIL-R2 ^[1]								
In Vitro	<p>The combination of Cisplatin (HY-17394) with Lexatumumab synergistically inhibits the cell growth and enhanced apoptotic death^[1].</p> <p>Lexatumumab (0-10 µg/ml, 72 h) induces various degrees of cell death in the different melanoma cell lines^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Melanoma cell lines</td> </tr> <tr> <td>Concentration:</td> <td>0.01, 0.1, 1.0 and 10.0 µg/ml</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Induced various degrees of cell death in the different cell lines.</td> </tr> </table>	Cell Line:	Melanoma cell lines	Concentration:	0.01, 0.1, 1.0 and 10.0 µg/ml	Incubation Time:	72 h	Result:	Induced various degrees of cell death in the different cell lines.
Cell Line:	Melanoma cell lines								
Concentration:	0.01, 0.1, 1.0 and 10.0 µg/ml								
Incubation Time:	72 h								
Result:	Induced various degrees of cell death in the different cell lines.								
In Vivo	<p>Lexatumumab (10 mg/kg, i.v., twice a week) increases antitumor effect in vivo when combined with Dacarbazine (HY-B0078)^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>FEMX-1 xenografts mice^[2]</td> </tr> <tr> <td>Dosage:</td> <td>10 mg/kg, 10 mg/kg+Dacarbazine (62.5 mg/kg once a week, i.p. injection)</td> </tr> <tr> <td>Administration:</td> <td>i.v., twice a week</td> </tr> <tr> <td>Result:</td> <td>Increased antitumor effect in vivo when combined with Dacarbazine (HY-B0078). Induced cleavage of livin into its truncated, proapoptotic form, a compound previously shown to accelerate apoptosis.</td> </tr> </table>	Animal Model:	FEMX-1 xenografts mice ^[2]	Dosage:	10 mg/kg, 10 mg/kg+Dacarbazine (62.5 mg/kg once a week, i.p. injection)	Administration:	i.v., twice a week	Result:	Increased antitumor effect in vivo when combined with Dacarbazine (HY-B0078). Induced cleavage of livin into its truncated, proapoptotic form, a compound previously shown to accelerate apoptosis.
Animal Model:	FEMX-1 xenografts mice ^[2]								
Dosage:	10 mg/kg, 10 mg/kg+Dacarbazine (62.5 mg/kg once a week, i.p. injection)								
Administration:	i.v., twice a week								
Result:	Increased antitumor effect in vivo when combined with Dacarbazine (HY-B0078). Induced cleavage of livin into its truncated, proapoptotic form, a compound previously shown to accelerate apoptosis.								

REFERENCES

- [1]. Belyanskaya LL, et al. Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer. 2007 Oct 22;6:66.
- [2]. Engesæter B, et al. Dacarbazine and the agonistic TRAIL receptor-2 antibody lexatumumab induce synergistic anticancer effects in melanoma. PLoS One. 2012;7(9):e45492.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA